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Abstract: Infections caused by bacteria resistant to antibiotics are an increasing problem. Multivalent
antibiotics could be a solution. In the present study, a covalent conjugate between Ciprofloxacin and
a G0-PAMAM dendrimer has been synthesized and tested against clinically relevant Gram-positive
and Gram-negative bacteria. The conjugate has antimicrobial activity and there is a positive dendritic
effect compared to Ciprofloxacin itself.
Keywords: antimicrobial compounds; dendrimers; Ciprofloxacin
1. Introduction
Antimicrobial resistance to antibiotics is an increasing problem worldwide. Accordingly, the World
Health Organization (WHO) has listed antibiotic resistance as one of the three most important public
health challenges in the 21st century [1]. Two major causes for the present situation are the over
prescription of antibiotics leading to resistance and the lack of new antibiotics. Bacterial resistance
occurs via different mechanisms including degradation of the antimicrobial compound, modification
of the antimicrobial target, decrease in drug uptake, global regulatory changes in metabolic pathways,
and the activation of efflux mechanisms [2,3]. Resistance due to the expression of efflux-pumps is
problematic, because such pumps are not very specific with respect to antibiotics, but are capable
of exporting a wide variety of different classes of antimicrobial compounds, potentially causing
multi-resistance [4–9].
A number of compounds which are inhibitors of efflux-pumps are known, and many of the
classical drugs ranging from antihistamines to CNS-active compounds from psychiatry have this
interesting side-effect, i.e., they are efflux-pump inhibitors at low concentrations but kill bacteria at
higher concentrations [10–14]. Apart from the effect on the central nervous system, a serious issue is
that the known efflux-pump inhibitors lack specificity for bacterial efflux pumps, but are also inhibitors
for pumps found in humans, like glycoprotein P, and can interfere with the hERG-channel in the heart
lengthening the QT-interval, increasing the risk of cardiac arrest [15,16].
A possible solution to efflux-mediated resistance could be modifications of known antibiotics so
they are not substrates for efflux-pumps while keeping the antimicrobial activity.
D’Emanuele and coworkers [17] discovered that the beta-blocker propranolol covalently
conjugated to a PAMAM-dendrimer was internalized by human cells. This was interesting, because
propranolol itself is known to be a substrate for the glycoprotein P pump.
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Since all families of efflux pumps [8] are highly promiscuous with respect to substrates, this led
us to the idea of using a conjugate between a dendrimer and an antibiotic to enter the bacteria and
prevent export by their efflux pumps.
The conjugation of an antibiotic to a dendrimer can be either non-covalent or covalent:
Non-covalent attachment requires the formation of a guest–host complex between the antibiotic
and the dendrimer that is sufficiently stable to survive the gastrointestinal system and in the blood
stream, while either having an antimicrobial effect as a complex or releasing the antibiotic once inside
the bacteria.
Xu and coworkers [18] studied the solubilization of the fluoroquinolones Nadifloxacin and
Prulifloxazin in amino-terminated ethylenediamine-core PAMAM-dendrimers (EDA-core PAMAM)
and found no effect on the solubility at low pH, which shows that a non-covalent complex could
dissociate in the stomach and undergo uptake as two separate entities. In vitro, there was an
enhanced antibacterial effect of combining Prulifloxacin with the G4-dendrimer (64 NH2-groups at the
surface) against E. coli. Wen and coworkers [19] found that the complex between amino-terminated
EDA-core PAMAM-dendrimers and Sulfomethoxazole showed enhanced activity in vitro against
E. coli. There have also been in vitro studies on the effect of co-administering antibiotics with
poly(propylene imine) dendrimers showing similar results [20]. Antimicrobial dendrimers are also
known and some examples are the quaternary silicon-dendrimers pioneered by de la Mata, Gomez and
coworkers [21–24] the small peptide-dendrons by Urbanczyk-Lipkowska and coworkers [25–28] and
the peptide dendrimers by Reymond and coworkers [29–32].
Covalent conjugates between antibiotics have been described by Kannan and coworkers [33],
who synthesized a covalent conjugate between Azithromycin and a hydroxyl-terminated generation 4
PAMAM-dendrimer that released the antibiotic after cellular uptake enabling treatment of intracellular
C. trachomatis in vitro. Baker and coworkers [34] described a photocleavable conjugate between a
dendrimer and Ciprofloxacin that released the drug upon illumination.
In the present work, we wanted to investigate if a dendrimer-antibiotic conjugate could have
antimicrobial activity in itself and not just be an advanced and expensive drug-delivery system. It was
important to choose an antibiotic, where the mechanism of activity was non-covalent interactions with
a target, because in that way it might be possible to kill many bacteria subsequently with the same
molecule in a “catalytic fashion”. The conjugate should optimally be active both towards Gram-positive
and Gram-negative bacteria. The dendrimer would have to be small, because access to the interior of
Gram-negative bacteria takes place through porines in the outer membrane that in general excludes
larger molecules from passage [35,36].
The fluoroquinolones (Figure 1) are often used for treatment of Gram-negative infections and a lot
is known regarding the effect of substitution on the ring systems. The carboxylic acid in position 3
and the carbonyl group in position 4 are essential for activity. Substitution in position 2 also leads to
reduced activity, while the substituent in position 1 controls specificity against Gram negative or Gram
positive bacteria. Position 7 is also important for specificity as well as serum half-life [37].
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2. Results
Ciprofloxacin (1) (Figure 2) was chosen because it is active both against Gram-positive and
Gram-negative bacteria and because it acts through non-covalent binding to topoisomerases.
Ciprofloxacin targets primarily topoisomerase II in Gram-negatives and primarily topoisomerase
IV in Gram-positives. It has furthermore a natural handle for attachment of a linker (the
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piperazine moiety) that should have minimal effect on the antimicrobial properties. A G0 DAB-core
PAMAM-dendrimer [38] (Figure 2) was chosen as a compromise between multivalency, solubility of
the conjugate and a wish to keep the molecular weight as low as possible.
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The synthesis is shown in Scheme 1 and started with protection of the piperazine in Ciprofloxacin
with a BOC-group converting the zwitterionic compound into the carboxylic acid (6) followed by
conversion into the fully protected ester (7), which was much easier to handle. Following deprotection
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of the BOC-group, compound (8) was reacted with Phenyl acrylate [39] to give (9). Phenyl esters
have very high selectivity for acylation of primary versus secondary amines [40–42], which is why
Michael-addition is observed instead of acylation. Reaction of phenyl ester (9) with the dendrimer (2)
gave the benzyl ester (10), which was deprotected by catalytic hydrogenation (H2/Pd(OH)2) to give
the desired product (4). The control compound (3) was synthesized by a similar route (Scheme 2),
but using benzyl acrylate [43] for the Michael addition and deprotection as for (4).Molecules 2019, 24, x FOR PEER REVIEW 4 of 13 
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Scheme 2. Synthe is of the Ciprofloxacin control derivative (3) from Ciprofloxacin Benzyl ester (8).
The dendrimer-control was synthesized by acetylation of the dendrimer (2) with excess
acetic anhydride.
The compounds were tested against four different strains of clinically relevant pathogens for
which antibacterial resistance is a challenge representing two Gram-positive (Enterococcus faecalis
and Staphylococcus aureus) and two Gram-negative species (Pseudomonas aeruginosa and Salmonella
enterica). The S. aureus 8325-4 strain is a plasmid cured variant of the NTCT 8325 variant, an important
model strain used in laboratory research [44,45]. The E. faecalis V583 strain (ATCC 700802, GenBank
AE016830.1) is a vancomycin-resistant, clinical isolate from human blood [46,47]. The S. enterica serovar
Typhimurium 4/74 strain represent a serovar commonly implicated in human gastroenteritis that is
also used as a mouse model of human typhoid fever [48]. The P. aeruginosa PAO1 strain is a commonly
used research strain for this opportunistic pathogen [49,50]. MIC-values for these target strains were
determined by microbroth dilution assay in 96-well microtiter plates. The results are shown in Table 1
and the minimal inhibitory concentrations (MIC values) are given both in mg/L and in µmol/L.
Table 1. MIC-values of the compounds tested in four different strains of pathogenic bacteria. The
MIC-values are the median of three biological replicates.
Bacterial Strain Compound MICmg/L
MIC
µM
Gram-positive
S. aureus 8325-4
1 0.25 0.75
3 0.5 1.24
4 16 0.0069
5 >256 >0.47
E. faecalis V583
1 0.25 0.75
3 0.5 1.24
4 16 0.0069
5 >256 >0.47
Gram-negative
S. enterica serovar Typhimurium 4/74
1 0.5 1.5
3 0.25 0.62
4 16 0.0069
5 >256 >0.47
P. aeruginosa PAO1
1 0.25 0.75
3 0.5 1.24
4 32 0.014
5 >256 >0.47
trends were observed for all four target organisms. However, our variant of the 4/74 strain
exh bited an unusual lack of sensitivity towards Ciprofloxacin with only 0.8% of the Salmonella strains
in the EUCAST database on antimicrobial wild type distributions exhibiting a similar or a higher MIC
value (https://mic.eucast.org/Eucast2/). The strain SL1344 that is a derivative of the 4/74 strain [48] has
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been reported as Ciprofloxacin sensitive [51,52]. Although the 4/74 variant used in our study can in fact
be described as resistant towards Ciprofloxacin it showed the same overall pattern in sensitivities as the
three other target species that were all sensitive to Ciprofloxacin according to the EUCAST database.
The control dendrimer (5) lacked antimicrobial activity whereas the dendrimer Ciprofloxacin
conjugate (4) showed highest activity in terms of MIC values expressed in µM showing a clear positive
dendritic effect, which becomes even bigger if the MIC values are calculated relative to the number of
Ciprofloxacines. This result emphasizes the strong synergistic activity of the dendrimer Ciprofloxacin
conjugate. In conclusion, this compound contributes to the overall antimicrobial activity of the
conjugate that is of interest as it moves its application beyond that of being a drug delivery vehicle.
3. Discussion
Successful penetration of the bacterial cell envelope is a prerequisite for the activity of antibiotics
having intracellular targets. At physiological pH, fluoroquinolones are known to coexist in a
zwitterionic and overall uncharged form and a neutral form, with only the latter form passively
diffusing through cell membranes, such as the cytoplasmic membrane of Gram-negatives and
Gram-positives [53]. For Gram-negatives, however, the outer membrane and its lipopolysaccharide
(LPS) layer constitute a second barrier. Penetration by fluoroquinolones of this barrier is suggested to
be mediated by three mechanisms: (i) by a hydrophilic pathway through porins, (ii) by a hydrophobic
pathway through the lipid bilayer, and (iii) by a “self-promoted” pathway involving displacement
of divalent cations bridging adjacent LPS molecules [54] such as seen for antimicrobial peptides.
In hydrophilic fluoroquinolones, such as Ciprofloxacin, uptake is mediated primarily by porins and by
the “self-promotion” pathway [55,56]. With Ciprofloxacin having a mass of 331 Da it is easily imagined
that this hydrophilic molecule can cross the water-filled porins as they generally have an exclusion
size of 600 Da [57]. However, the larger size of our dendrimer conjugate (876 Da), and the absence of
classical porins in Pseudomonas aeruginosa [58], suggests that these compounds are instead transported
by either the “self-promotion” pathway or by hijacking of specific channels and high affinity receptors
translocating larger nutrient molecules [57].
The mode of action of Ciprofloxacin is by stabilizing the complex of prokaryotic topoisomerase II
and IV enzymes, leading to DNA fragmentation and bacterial death [59,60]. The control dendrimer
showed in our study no antimicrobial activity which is in contrast with studies on PAMAM dendrimers
with terminated amino groups [61–63]. This result is most likely due to our control dendrimer was
equipped with terminal acetyl groups. The lack of antimicrobial activity of the control dendrimer
compared to the synergistic activity of the dendrimer Ciprofloxacin conjugate relative to Ciprofloxacin
suggest that the synergism is related to Ciprofloxacin mode of action. Here, it is of interest that PAMAM
dendrimers promote transfection of DNA in both mammalian cells [64] and in prokaryotic cells as
demonstrated for Anaplasma phagocytophilum, an obligate intracellular bacterium [65]. Thus, the ability
of PAMAM to bind DNA indicates that the dendrimer may interact with the association of Ciprofloxacin
with bacterial topoisomerases e.g., by binding to DNA fragments generated by Ciprofloxacin activity.
We have not in our study compared the synergy effect observed for the dendrimer Ciprofloxacin
covalent conjugate with the antimicrobial activities of mixtures of the dendrimer and Ciprofloxacin.
A synergy effect has also been observed for mixtures of PAMAM and quinolones or sulfamethoxazole
but this result appeared to be a concentration-dependent effect of the PAMAM dendrimer on the
solubility of the antimicrobial compounds. For the mixture of PAMAM and quinolones this effect was
also pH dependent. It was hypothesized that this could be due to electrostatically interactions between
PAMAM and the carboxyl group in the quinolone molecules and in addition that both quinolones
and sulfamethoxazole might be kept in the cavities of the PAMAM dendrimer resulting in increasing
solubility of the small guest molecules [18,19]. Thus, the synergy mechanism in mixtures appears to
differ from the mechanism for the covalent conjugate hypothesized above. This would make it difficult
to interpret the outcome of a potential comparative analysis.
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It will be of interest to examine further the mode of action of the dendrimer Ciprofloxacin conjugate
and to illuminate whether this compound may show antimicrobial activity towards Ciprofloxacin
resistant bacterial variants. Thus, it should be tested whether resistance due to mutations in the
protein targets of Ciprofloxacin might be circumvented by the potential DNA binding abilities of the
dendrimer. It is more straightforward to anticipate the overcome of resistance due to efflux pumps by
using PAMAM as the vehicle to transport Ciprofloxacin to the topoisomerase targets but this also need
to be tested experimentally. Such studies are in progress in our laboratories.
In conclusion, we have demonstrated proof of principle that the dendrimer Ciprofloxacin conjugate
exhibits increased antimicrobial activity and that PAMAM dendrimers have potential in antimicrobial
chemotherapy beyond acting as delivery vehicles. Such synergistic effects have been described
before for anionic/cationic dendrimers and levofloxacin, another fluoroquinolone in a non-covalent
system [66].
4. Experimental
4.1. Bacterial Cultures
Salmonella enterica serovar Typhimurium 4/74, Pseudomonas aeruginosa PAO1, Staphylococcus aureus
8325-4 and Enterococcus faecalis V583 from the local collection at the Institute were grown overnight with
shaking (180 rpm) in 5 mL Luria-Bertani (LB) broth at 37 ◦C for 18 h before use for MIC determinations.
4.2. MIC Determinations
MIC was determined by microbroth dilution assay in 96-well microtiter plates with LB broth
containing two-fold serial dilutions of test compounds. Test compounds were diluted in sterile water
and prepared for a testing concentration range of 0.25–256 µg/mL. Then, 50 µL from each dilution was
transferred into the well of a microtiter plate and inoculated with 50 µL of bacterial culture prepared
for a final concentration of approximately 106 CFU/mL corresponding roughly to OD600 0.00065.
The microtiter plates were then incubated aerobically at 37 ◦C for 18–24 h with shaking (180 rpm).
Growth in individual plate wells was defined as OD600 > 0.06. Wells containing only inoculums
were used as positive controls for bacterial growth, while wells with only media was used as negative
control for sterility of media.
The MIC values are the median of three biological replicates, and demonstrated
good reproducibility.
4.3. Synthetic Procedures
4.3.1. 7-(4-(2-Carboxyethyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3
-carboxylic acid (3)
To a round bottom flask equipped with a magnetic stirring bar was added compound 8 (1.6 g,
3.79 mmol) and dissolved in dichloromethane (40 mL). Benzyl acrylate (960 mg, 4.19 mmol) was added
and the reaction was stirred at RT for 72 h under nitrogen atmosphere. The yellow solution was
evaporated in vacuo, and dried under high vacuum. The pale-yellow powder was washed with Et2O
(30 mL) and further dried in high vacuum. The intermediate compound (11) was obtained as pale
white solid (1.05 g), which was used directly for the next step.
Compound (11) (1.0 g; 17.1 mmol) was dissolved in a 1:1 mixture of ethanol and THF (50 mL in
total), 10% Pd(OH) 2 on carbon (150 mg) was added and the mixture hydrogenated at 3 bar pressure at
room temperature for 16 h. The reaction mixture was filtered through Celite to remove the catalyst,
and compound (3) was obtained by removing all volatiles in vacuum. Yield: 580 mg (37%).
1H NMR (300 MHz, DMSO-d6): δ = 1.20–1.28 (m, 2H), 1.34–1.43 (m, 2H), 2.81–2.92 (m, 2H),
2.38–2.48 (m, 8 H), 2.57–2.58 (m, 2H), 3.85–3.95 (m, 1H), 7.60–6.69 (m, 1H), 7.92–8.05 (m, 1H), 8.68–8.75
(m, 1H). 13C NMR (126 MHz, DMSO-d6): δ 176.30; 172.87; 165.86; 153,91; 151.93; 147.87; 144.14; 139.09;
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118.69; 111.03; 106.69; 62.57; 52.58; 52.00; 51.64; 48.55; 47.11; 46.26; 42.40; 36.48; 35.93; 30.88; 7.54. 19F
NMR (470 MHz, DMSO-d6): δ −121.57. HRMS: ESI (0.1% Formic acid in MeOH): 404.161 (calcd. for
C20H22FN3O5+: m/z: 404.162).
4.3.2. DAB-PAMAM-G0-(Cipro-COOH)4 • 6HCl (4)
Compound (10) (0.27 g; 0.11 mmol) was dissolved in a mixture of THF and water (10:3 v/v;
60 mL) and added to 10% Pd(OH)2 on carbon (0.10 g) in a hydrogenation bottle. The mixture was
hydrogenated in a Parr-apparatus at 3.5 bar for 48 h. The catalyst was removed by filtration through a
bed of Celite and concentrated in vacuo. A solution of HCl in Methanol (1 M, 30 mL) was added and
the solution evaporated again. The hydrochloride was purified by size-exclusion chromatography on
Sephadex G25 (Pharmacia (Sweden) now GE Healthcare (US) using Methanol:H2O (1:1 v/v) as eluent.
After removal of the solvent, the product was obtained in a yield of 0.12 g (46%).
1H-NMR (500 MHz, DMSO-d6): δ 15.10 (s, 3 H); 8.69–8.61 (m, 4 H); 7.96–7.84 (m, 4 H); 7.65–7.53
(m, 4 H); 3.89–3.82 (m, 4 H); 3.41–3.23 (m, 48 H); 3.14 (s, 16 H); 3.11–3.06 (m, 8 H); 2.90–2.85 (m, 3 H);
2.71–2.67 (m, 8 H); 1.80–1.73 (m, 4 H); 1.37–1.29 (m, 8 H); 1.22–1.13 (m, 8 H). 13C-NMR (126 MHz,
DMSO-d6): δ 176,29; 169.17; 165.79; 153.80; 151.80; 148.08; 139.03; 119.11; 111.18; 111.00; 106.80;
106.71; 51.56; 50.88; 48.61; 39.52; 38.41; 38.28; 36.49; 35.98; 29.39; 25.13; 7.63. 19F-NMR (470 MHz,
DMSO-d6): δ −121.67. HRMS: ESI (0.1% Formic acid in MeOH): m/z [M + 2H+]2+: 1044.0084 (calcd.
for C104H134F4N22O202+: 1044.0052); m/z [M + 3H+]3+: 696.3405. (calcd. for C104H135F4N22O203+:
696.3392); m/z [M + 4H+]4+: 522.0033. (calcd. for C104H136F4N22O203+: 522.5062).
4.3.3. DAB-PAMAM-G0-(Acetamide)4 • 2HCl (5)
DAB-PAMAM-G0-(NH2)4 [34] (1.00 g; 1.84 mmol) was dissolved in ethanol (25 mL).
Acetic anhydride (7.50 g; 73.5 mmol) was added and the reaction mixture was stirred at room
temperature for 16 h. The reaction mixture was evaporated in vacuo, dissolved in 1 M HCl in Methanol
(25 mL) and evaporated again. The residue was redissolved in 1 M HCl in Methanol (10 mL) and
added dropwise to Diethyl ether (200 mL) under stirring. The precipitated product was filtered and
dried in vacuum to give a white crispy solid. Yield: 1.44 g (quantitative). Ninhydrin-test for residual
primary amino groups (1% Ninhydrin in ethanol): Negative after 24 h.
1H-NMR (500 MHz, D2O): δ 3.45-3.39 (m, 8 H); 3.25 (s, 20 H); 2.78–2.69 (m, 8 H); 1.93 (s, 12 H).
13C-NMR (126 MHz, D2O): δ 174.37; 171.86; 52.46; 49.60; 38.68; 28.74; 28.70; 21.82; 20.54. HRMS
(MALDI, matrix: Dithranol): m/z [M+H+]+: 713.4682 (calcd. for C32H60N10O6: 713.4686); [M + Na+]+:
735.4503 (calcd. for. C32H60N10NaO6+: 735.4503); [M + K+]+: 751.4155 (calcd. for. C32H60N10KO6+:
751.4277).
4.3.4. Benzyl 7-(4-tert-butoxycarbonyl)piperazin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline
-3-carboxylate (7)
To a flame dried round bottomed flask equipped with a magnetic stirring bar was added:
Ciprofloxacin (1) (1.50 g; 4.53 mmol); 1,4-dioxane (25 mL); Boc2O (1.19 g; 5.45 mmol) and Et3N (0.76 mL;
5.45 mmol). The reaction mixture was stirred at room temperature for 3 h and evaporated to dryness
in vacuo. The residue was dissolved in acetonitrile (50 mL) and benzyl chloride (0.69 g; 5.45 mmol),
K2CO3 (0.75 g; 5.43 mmol) was added. This reaction mixture was refluxed for 10 h and evaporated in
vacuo to give a yellow powder, that was washed with heptane (100 mL), water (100 mL) and heptane
(100 mL) followed by drying in high vacuum. White powder. Yield 2.23 (94%).
1H-NMR (500 MHz, CDCl3): δ 8.50 (s, 1 H); 8.00 (d, J = 13.2 Hz, 1 H); 7.50 (d, J = 7.5 Hz, 2 H);
7.36 (t, J = 7.4 Hz, 2 H); 7.30 (t, J = 7.3 Hz, 2 H); 5.37 (s, 2 H); 3.65 (t, J = 5.1 Hz, 4 H); 3.47–3.41 (m,
1 H); 3.22 (t, J = 4.8 Hz, 4 H); 1.49 (s, 9 H); 1.28 (q, J = 6.9 Hz, 2 H), 1.10 (q, J = 6.6 Hz, 2 H). 13C-NMR
(126 MHz, CDCl3): δ 172.94; 165.63; 154.72; 154.48; 152.50; 148.44; 144.51; 138.15; 136.48; 128.64; 128.11;
128.05; 123.18; 113.55; 113.37; 110.07; 105.32; 80.34; 66.56; 50.10; 34.81; 28.54; 8.29. 19F-NMR (470 MHz,
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CDCl3): δ −123.48. HRMS: ESI (0.1% Trifluoroacetic acid in MeOH): m/z [M + H+]+: 522.2356 (calcd.
for C29H33FN3O5+: 522.2399); m/z [M + 2H+]2+: 261.1219 (calcd. for C29H33FN3O52+: 522.2399).
4.3.5. Benzyl 1-cyclopropyl-6-fluoro-4-oxo-piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate (8)
Compound (7) (0.53 g; 1.02 mmol) was dissolved in a mixture of trifluoroacetic acid and
dichloromethane (2:8 v/v, 5 mL) and stirred at room temperature for 24 h. The reaction mixture was
diluted with dichloromethane and washed with saturated aqueous NaHCO3 to remove the acid.
The organic phase was dried over MgSO4, filtered and evaporated in vacuo to give the deprotected
amine (8) as a powder. Yield: 0.39 g (90%).
1H-NMR (500 MHz, CDCl3): δ 8.47 (s, 1 H); 7.95 (d, J = 13.2 Hz, 1 H); 7.49 (d, J = 7.0 Hz, 2 H); 7.36
(d, J = 7.6 Hz, 2 H); 7.31–7.27 (m, 1 H), 7.23 (d, J = 7.1 Hz, 1 H); 5.35 (s, 2 H); 3.42–3.37 (m, 1 H); 3.29–3.22
(m, 4 H); 3.13–3.07 (m, 4 H); 2.59 (s, 1 H); 1.29–1.23 (m, 2 H), 1.11–1.06 (m, 2 H). 13C-NMR (126 MHz,
CDCl3): δ 173.20; 165.46; 154.49; 152.51; 148.33; 138.07; 136.54; 128.60; 128.07; 128.01; 113.33; 113.14;
109.94; 104.93; 77.16; 66.40; 50.88; 45.88; 34.68; 8.22. 19F-NMR (470 MHz, CDCl3): δ −123.50. HRMS:
ESI (0.1% Trifluoroacetic acid in MeOH): m/z [M + H]+: 422.1875 (calcd. for C24H25FN3O5+: 422.1875).
4.3.6. Benzyl 1-cyclopropyl-6-fluoro-4-oxo-7-(4-(3-oxo-3-phenoxypropyl)piperazin-1-yl)-1,4
-dihydroquinoline-3-carboxylate (9)
To a flame dried round bottomed flask equipped with a magnetic stirring bar was added:
Compound (8) (1.00 g; 2.37 mmol), dichloromethane (25 mL) and phenyl acrylate [35] (0.3885 g;
2.62 mmol). The mixture was stirred under N2 for 72 h and evaporated in vacuo. The residual powder
was washed with diethyl ether (20 mL) and dried in vacuum giving compound (9) as a white powder.
Yield: 1.27 g (94%).
1H-NMR (500 MHz, CDCl3): δ 8.47 (s, 1 H); 7.95 (d, J = 13.3 Hz, 1 H); 7.50 (d, J = 7.0 Hz, 2 H);
7.39–7.34 (m, 4 H); 7.31–7.27 (m, 1 H); 7.24–7.20 (m, 2 H); 7.11–7.08 (m, 2 H); 5.36 (s, 2 H); 3.41–3.37 (m,
1 H); 3.30 (t, J = 4.8 Hz, 4 H); 2.93 (t, J = 6.9 Hz, 2 H); 2.81 (t, J = 7.1 Hz, 2H); 2.79–2.75 (m, 4 H), 1.27–1.22
(m, 2 H); 1.10 (m, 2 H). 13C-NMR (126 MHz, CDCl3): δ 173.08; 170.90; 165.47; 154.40; 152.42; 150.76,
148.34; 138.03; 136.56; 129.53; 128.59; 128.04; 127.97; 125.97; 122.99; 122.93; 121.59; 113.28; 113.10; 109.99;
104.95; 77.16; 66.38; 53.50; 52.74; 49.90; 34.65; 32.60; 8.18. 19F-NMR (470 MHz, CDCl3): δ−123.41. HRMS:
ESI (0.1% Trifluoroacetic acid in MeOH): m/z [M+H+]+: 570.2415 (calcd. for C23H33FN3O5+: 570.2399);
m/z [M + 2H+]2+: 285.6224 (calcd. for C29H33FN3O52+: 285.6236); m/z [M + Na+]+: 592.2235 (calcd. for
C23H33FN3NaO5+: 592.2219); m/z [M + K+]+: 608.1961 (calcd. for C23H33FN3KO5+: 608.7204).
4.3.7. DAB-PAMAM-G0-(Cipro-Bn)4 (10)
In a flame dried round bottomed flask equipped with a magnetic stirring bar was compound
(8) (0.50 g; 0.88 mmol) dissolved in dry DMSO (10 mL). The solution was heated to +40 ◦C and
4-(Dimethylamino)pyridine (0.0108 g; 0.088 mmol) was added followed by dropwise addition of a
solution of DAB-PAMAM-G0-(NH2)4 [34] (0.100 g; 0.184 mmol). The reaction mixture was stirred
for 4 days at 40 ◦C under a N2-atmosphere and then transferred to a dialysis bag (Regenerated
cellulose, molecular weight cut-off 1 kD) and dialyzed against 0.2 M HCl (2 × 2 L, 24 h each) followed
by milliQ-water (2 × 2 L, 24 h each). The content of the dialysis bag was then transferred to a
round bottomed flask and lyophilized to give the benzylester protected dendrimer conjugate (10),
which contains encapsulated phenol as evidenced from NMR. Yield 0.36 g (80%). Ninhydrin-test for
residual primary amino groups (1% Ninhydrin in ethanol): Negative after 24 h.
1H-NMR (500 MHz, DMSO-d6): δ 8.44 (d, J = 19.7 Hz, 4 H); 8.38–8.20 (m, 5 H, included phenol);
7.73 (m, 4 H); 7.51–7.45 (m, 8 H); 7.45–7.42 (m, 3 H); 7.42–7.36 (m, 12 H); 7.34–7.30 (m, 4 H); 5.28–5.24
(m, 8 H); 3.67–3.62 (m, 4 H); 3.52–3.28 (m, 24 H); 3.25–3.17 (m, 8 H); 3.13 (s, 16 H); 3.10–2.85 (m,
24 H); 2.85–2.73 (m, 4 H); 2.66–2.58 (m, 8 H); 1.75–1.65 (m, 3 H); 1.26–1.21 (m, 8 H); 1.11–1.06 (m, 8 H).
13C-NMR (126 MHz, DMSO-d6): δ 171,55; 171.47; 164.48; 164.44; 153.53; 153.38; 151.57; 151.42; 150.46
(phenol); 148.42; 137.99; 137.92; 136,61; 129.49 (phenol); 128.35; 127.73; 127.58; 125.81 (phenol); 122.11;
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121.76 (phenol); 111.70; 111.52; 108.79; 106.35; 65.22; 52.34; 51.90; 51.74; 51.54; 51.39; 49.33; 48.72; 48.27;
39.52; 38.45; 38.24; 36.47; 34.84; 30.41; 7.53. 19F-NMR (470 MHz, DMSO-d6): δ −124.29. HRMS: ESI
(0.1% Formic acid in MeOH): m/z [M + 2H+]2+: 1224.1091 (calcd. for C132H158F4N22O202+: 1224.0991);
m/z [M + 3H+]3+: 816.4073. (calcd. for C132H159F4N22O203+: 816.4018; m/z [M + 4H+]4+: 612.5532).
(calcd. for C132H160F4N22O204+: 612.5532).
NMR & MS spectra of the compounds are available in Supplementary Materials.
5. Conclusions
Ciprofloxacin has been conjugated to a DAB-core G0 PAMAM-dendrimer and the antimicrobial
activity has been tested on a selection of both Gram-positive and Gram-negative bacteria of clinical
relevance. A positive dendritic effect is observed for the conjugate in both types of bacteria. This is an
example of a dendrimer that adds to the antimicrobial activity of a conjugate which could lead to new
strategies for the treatment of infectious diseases.
Supplementary Materials: The following are available online. NMR & MS spectra of the compounds.
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